CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...